FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3040946598> ?p ?o ?g. }

• W3040946598 endingPage "S140" @default.
• W3040946598 startingPage "S139" @default.
• W3040946598 abstract "Oxaliplatin-based chemotherapies are widely used in the treatment of gastrointestinal cancers. However, several studies have reported that oxaliplatin-induced sinusoidal obstruction syndrome (SOS)/hepatic veno-occlusive disease (VOD) has occurred, with an incidence of 19% to 78%. SOS/VOD was associated with postoperative morbidity and decreased overall survival. SOS/VOD induced by oxaliplatin lacks specific clinical symptoms, which makes it difficult to diagnose SOS/VOD based on clinical criteria. Recently, image diagnosis is expected as a new diagnostic method. In the mechanism of SOS/VOD, the sinusoidal endothelial cell damage hinders the outflow of sinusoid by embolization, leading to portal hypertension resulting in increased spleen volume. A previous study reported that the increase in spleen volume was a diagnostic indicator of SOS/VOD, which achieved a specificity of 90%. Several studies evaluated the risk of SOS/VOD, using increase in spleen volume on computed tomography (CT) within 6 months after the administration of oxaliplatin. Transabdominal ultrasonography (US) is also expected as a novel diagnostic method, since US accompanied by Doppler imaging enables the visualization of blood flow abnormalities without radiation exposure. Recent studies reported a US diagnostic scoring system was useful for SOS/VOD after hematopoietic stem cell transplantation. The US scoring system is called HokUS-10, and we expect HokUS-10 may make it possible to early detect blood flow abnormalities before the increase in spleen volume is detected by CT. We herein prospectively evaluated the accuracy of HokUS-10 for SOS/VOD associated with oxaliplatin-based chemotherapy. This study started as a single center, prospective observational study in December 2019. The patients with gastrointestinal cancer who are planned to receive oxaliplatin-based chemotherapy are eligible for this study. The exclusion criteria are a history of oxaliplatin in past treatment, cirrhosis or chronic hepatitis, and liver resection. The US scoring of HokUS-10 is performed before oxaliplatin-based chemotherapy and 2, 4, 6, 12 months after the start of the administration of oxaliplatin. HokUS-10 consists of 10 parameters: hepatomegaly in the (1) left lobe and (2) right lobe, (3) gallbladder wall thickening, (4) portal vein (PV) diameter, (5) paraumbilical vein (PUV) diameter, (6) amount of ascites, (7) PV mean velocity, (8) direction of PV flow, (9) appearance of PUV blood flow signal, (10) hepatic artery resistance-index. The endpoint of this study is a probability that a high score of HokUS-10 and an increase in spleen volume on CT are observed in the same case. If patients undergo hepatectomy or liver biopsy after oxaliplatin-based chemotherapy, we also compare the score of HokUS-10 with histopathological diagnosis. A total of 30 cases are planned for registration within 2.5 years. This study was approved by the institutional review board of Hokkaido University Hospital (approval number: 019-0133). Clinical trial information: UMIN000045275. We would like to express special thanks to all participating investigators. The author." @default.
• W3040946598 created "2020-07-16" @default.
• W3040946598 creator A5001876291 @default.
• W3040946598 creator A5008729234 @default.
• W3040946598 creator A5016320560 @default.
• W3040946598 creator A5018567359 @default.
• W3040946598 creator A5024713150 @default.
• W3040946598 creator A5026656732 @default.
• W3040946598 creator A5032420302 @default.
• W3040946598 creator A5036752323 @default.
• W3040946598 creator A5042795088 @default.
• W3040946598 creator A5048421476 @default.
• W3040946598 creator A5054182211 @default.
• W3040946598 creator A5064251335 @default.
• W3040946598 creator A5065311916 @default.
• W3040946598 creator A5088885352 @default.
• W3040946598 date "2020-07-01" @default.
• W3040946598 modified "2023-09-27" @default.
• W3040946598 title "P-153 Novel ultrasonographic scoring system of sinusoidal obstruction syndrome associated with oxaliplatin-based chemotherapy in patients with gastrointestinal cancer" @default.
• W3040946598 doi "https://doi.org/10.1016/j.annonc.2020.04.235" @default.
• W3040946598 hasPublicationYear "2020" @default.
• W3040946598 type Work @default.
• W3040946598 sameAs 3040946598 @default.
• W3040946598 citedByCount "0" @default.
• W3040946598 crossrefType "journal-article" @default.
• W3040946598 hasAuthorship W3040946598A5001876291 @default.
• W3040946598 hasAuthorship W3040946598A5008729234 @default.
• W3040946598 hasAuthorship W3040946598A5016320560 @default.
• W3040946598 hasAuthorship W3040946598A5018567359 @default.
• W3040946598 hasAuthorship W3040946598A5024713150 @default.
• W3040946598 hasAuthorship W3040946598A5026656732 @default.
• W3040946598 hasAuthorship W3040946598A5032420302 @default.
• W3040946598 hasAuthorship W3040946598A5036752323 @default.
• W3040946598 hasAuthorship W3040946598A5042795088 @default.
• W3040946598 hasAuthorship W3040946598A5048421476 @default.
• W3040946598 hasAuthorship W3040946598A5054182211 @default.
• W3040946598 hasAuthorship W3040946598A5064251335 @default.
• W3040946598 hasAuthorship W3040946598A5065311916 @default.
• W3040946598 hasAuthorship W3040946598A5088885352 @default.
• W3040946598 hasBestOaLocation W30409465981 @default.
• W3040946598 hasConcept C121608353 @default.
• W3040946598 hasConcept C126322002 @default.
• W3040946598 hasConcept C126838900 @default.
• W3040946598 hasConcept C2776694085 @default.
• W3040946598 hasConcept C2777408962 @default.
• W3040946598 hasConcept C2779134260 @default.
• W3040946598 hasConcept C2780895475 @default.
• W3040946598 hasConcept C2780931953 @default.
• W3040946598 hasConcept C2780962732 @default.
• W3040946598 hasConcept C526805850 @default.
• W3040946598 hasConcept C71924100 @default.
• W3040946598 hasConceptScore W3040946598C121608353 @default.
• W3040946598 hasConceptScore W3040946598C126322002 @default.
• W3040946598 hasConceptScore W3040946598C126838900 @default.
• W3040946598 hasConceptScore W3040946598C2776694085 @default.
• W3040946598 hasConceptScore W3040946598C2777408962 @default.
• W3040946598 hasConceptScore W3040946598C2779134260 @default.
• W3040946598 hasConceptScore W3040946598C2780895475 @default.
• W3040946598 hasConceptScore W3040946598C2780931953 @default.
• W3040946598 hasConceptScore W3040946598C2780962732 @default.
• W3040946598 hasConceptScore W3040946598C526805850 @default.
• W3040946598 hasConceptScore W3040946598C71924100 @default.
• W3040946598 hasLocation W30409465981 @default.
• W3040946598 hasOpenAccess W3040946598 @default.
• W3040946598 hasPrimaryLocation W30409465981 @default.
• W3040946598 hasRelatedWork W102477170 @default.
• W3040946598 hasRelatedWork W1965756961 @default.
• W3040946598 hasRelatedWork W1973533688 @default.
• W3040946598 hasRelatedWork W2037724349 @default.
• W3040946598 hasRelatedWork W2379856106 @default.
• W3040946598 hasRelatedWork W2381828897 @default.
• W3040946598 hasRelatedWork W2394588226 @default.
• W3040946598 hasRelatedWork W2465617904 @default.
• W3040946598 hasRelatedWork W2545945608 @default.
• W3040946598 hasRelatedWork W2983270631 @default.
• W3040946598 hasVolume "31" @default.
• W3040946598 isParatext "false" @default.
• W3040946598 isRetracted "false" @default.
• W3040946598 magId "3040946598" @default.
• W3040946598 workType "article" @default.